Загрузка...
Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line
BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is the most common liver cancer with high mortality rate in patients suffering from liver diseases. The drug of choice used in advanced-stage of HCC is sorafenib. However, adaptive resistance has been observed in HCC patients undergoing long-term soraf...
Сохранить в:
| Опубликовано в: : | Clin Mol Hepatol |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
The Korean Association for the Study of the Liver
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6940489/ https://ncbi.nlm.nih.gov/pubmed/31564085 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2019.0031 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|